Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · IEX Real-Time Price · USD
40.73
+0.65 (1.62%)
Mar 27, 2024, 4:00 PM EDT - Market closed

Halozyme Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017201620152014 2013 - 2001
Net Income
281.59202.13402.71129.09-72.24-80.3362.97-103.02-32.23-68.38
Upgrade
Depreciation & Amortization
84.8649.6433.284.072.392.162.411.681.76
Upgrade
Share-Based Compensation
36.6224.420.8217.234.7835.730.6725.5920.8415.27
Upgrade
Other Operating Activities
-14.5-36.06-127.09-94.12-52.03-7.2538.2524.65-27.373.82
Upgrade
Operating Cash Flow
388.57240.11299.4455.45-85.42-49.5134.05-50.38-37.08-47.52
Upgrade
Operating Cash Flow Growth
61.83%-19.81%439.98%-------
Upgrade
Capital Expenditures
-15.2921.2-1.46-1.43-4.04-4.66-1.35-3.14-2.36-1.37
Upgrade
Acquisitions
0-999.1200000000
Upgrade
Change in Investments
-81.62490.92-404.8379.78-1.517.16-162.38-73.638.25-31.58
Upgrade
Investing Cash Flow
-96.91-487.01-406.2978.35-5.552.49-163.73-76.775.89-32.95
Upgrade
Share Issuance / Repurchase
-394.5-185.95-337.52-86.72-185.7713.72147.651.8713.1114.5
Upgrade
Debt Issued / Paid
-13.48617.44415.39-19.56338.99-77.52-16148.7600
Upgrade
Other Financing Activities
--69.12--------
Upgrade
Financing Cash Flow
-407.99362.3777.87-106.28153.22-63.8131.66150.6213.1114.5
Upgrade
Net Cash Flow
-116.33115.48-28.9827.5262.24-110.8101.9823.47-18.134.03
Upgrade
Free Cash Flow
373.28261.31297.9854.03-89.46-54.16132.7-53.52-39.44-48.89
Upgrade
Free Cash Flow Growth
42.85%-12.31%451.55%-------
Upgrade
Free Cash Flow Margin
45.01%39.58%67.22%20.19%-45.65%-35.67%41.91%-36.48%-29.20%-64.89%
Upgrade
Free Cash Flow Per Share
2.831.912.120.40-0.62-0.380.97-0.42-0.31-0.40
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).